Lovastatin
[CAS# 75330-75-5]

Identification

• Classification: API >> Circulatory system medication >> Regulating blood lipids
• Name: Lovastatin
• Synonyms: 1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-[2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl]-1-naphthalenyl 2-methylbutanoate
• Molecular Formula: C₂₄H₃₆O₅
• Molecular Weight: 404.54
• CAS Registry Number: 75330-75-5
• EC Number: 692-955-0
• SMILES: CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C

Properties

• Density: 1.1±0.1 g/cm³ Calc.^*
• Melting point: 175 °C (Expl.)
• Boiling point: 559.2±50.0 °C 760 mmHg (Calc.)^*
• Flash point: 185.3±23.6 °C (Calc.)^*
• Solubility: DMSO 8 mg/mL, Water $lessThan$1 mg/mL (Expl.)
• Index of refraction: 1.532 (Calc.)^*

^* Calculated using Advanced Chemistry Development (ACD/Labs) Software.

Safety Data

• Hazard Symbols: GHS07;GHS08 Danger
• Risk Statements: H302-H317-H351-H361-H372
• Safety Statements: P203-P260-P261-P264-P270-P272-P280-P301+P317-P302+P352-P318-P319-P321-P330-P333+P317-P362+P364-P405-P501

Hazard Classification

Hazard	Class	Category Code	Hazard Statement
Reproductive toxicity	Repr.	2	H361
Acute toxicity	Acute Tox.	4	H302
Specific target organ toxicity - repeated exposure	STOT RE	1	H372
Carcinogenicity	Carc.	2	H351
Skin sensitization	Skin Sens.	1	H317
Chronic hazardous to the aquatic environment	Aquatic Chronic	3	H412
Specific target organ toxicity - single exposure	STOT SE	3	H335
Skin irritation	Skin Irrit.	2	H315
Eye irritation	Eye Irrit.	2A	H319
Eye irritation	Eye Irrit.	2	H319
Reproductive toxicity	Repr.	1B	H360
Chronic hazardous to the aquatic environment	Aquatic Chronic	4	H413
Carcinogenicity	Carc.	1B	H350

Discovery and Applications

Lovastatin is a naturally occurring statin, classified as a member of the fungal polyketide family, used clinically as a cholesterol-lowering agent. Its molecular formula is C24H36O5. Structurally, lovastatin contains a hexahydro-naphthalene core fused to a lactone ring and a side chain that mimics the substrate of HMG-CoA reductase, the key enzyme in cholesterol biosynthesis. It appears as a white to off-white crystalline powder that is practically insoluble in water but soluble in organic solvents such as ethanol, methanol, and dichloromethane.

The discovery of lovastatin dates to the 1970s when it was isolated from the fungus *Aspergillus terreus*. Its development was driven by the need for pharmacological agents to lower plasma cholesterol and reduce the risk of cardiovascular disease. Lovastatin functions as a competitive inhibitor of HMG-CoA reductase, decreasing the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis. This results in lower levels of low-density lipoprotein cholesterol (LDL-C) and modest increases in high-density lipoprotein cholesterol (HDL-C).

The industrial production of lovastatin is primarily achieved through fermentation using *Aspergillus* species under controlled conditions. The fungus is cultured in nutrient-rich media to optimize polyketide synthesis, and the lovastatin is subsequently extracted using organic solvents. Purification involves crystallization or chromatographic techniques to yield the biologically active lactone form. Semi-synthetic derivatives, such as simvastatin, are prepared by chemical modification of lovastatin to enhance pharmacokinetic or pharmacodynamic properties.

Chemically, lovastatin exists as a lactone that can be hydrolyzed in vivo to the corresponding β-hydroxy acid, which is the active inhibitor of HMG-CoA reductase. The molecule contains multiple chiral centers, and its biological activity is highly stereospecific. The lactone ring and hexahydro-naphthalene scaffold allow binding to the enzyme’s active site, mimicking the natural substrate. Lovastatin is stable under normal storage conditions but can undergo hydrolysis or oxidation under strong acidic, basic, or oxidative conditions.

In practical applications, lovastatin is prescribed to patients with hypercholesterolemia and dyslipidemia to reduce cardiovascular risk. It is administered orally and metabolized primarily by hepatic cytochrome P450 enzymes. Beyond its cholesterol-lowering effects, lovastatin has been studied for potential pleiotropic benefits, including anti-inflammatory, antioxidant, and endothelial function-improving activities. Lovastatin is also used as a lead compound in medicinal chemistry for the development of other statins with improved potency, bioavailability, or reduced side effects.

Physically, lovastatin should be stored in a cool, dry environment, protected from light and moisture to prevent hydrolysis of the lactone ring. Handling precautions include avoiding inhalation or contact with skin and eyes, as with other pharmaceutical powders. The compound is non-volatile and stable under ambient laboratory conditions.

Overall, lovastatin is a clinically significant natural statin that serves as a model for cholesterol-lowering therapy. Its ability to inhibit HMG-CoA reductase, combined with the polyketide structure derived from fungal biosynthesis, makes it a cornerstone in cardiovascular pharmacotherapy and a template for the development of additional statin drugs.

References

2025. Lovastatin inhibits adipocyte-associated increased proliferation, EMT and aggressiveness of breast cancer cells. Medical Oncology, 42(8).
DOI: 10.1007/s12032-025-02874-3

2025. Heat capacity and thermodynamic functions of crystalline and amorphous forms of Lovastatin. Scientific Reports.
DOI: 10.1038/s41598-025-05075-0